Suppr超能文献

微小RNA在去势抵抗性前列腺癌中的作用

The role of microRNA in castration-resistant prostate cancer.

作者信息

Thieu William, Tilki Derya, de Vere White Ralph, Evans Christopher P

机构信息

Department of Urology, University of California, Davis, Medical Center, Sacramento, CA, USA.

出版信息

Urol Oncol. 2014 Jul;32(5):517-523. doi: 10.1016/j.urolonc.2013.11.004.

Abstract

INTRODUCTION

Castration-resistant prostate cancer (CRPC) has a historically low median survival rate, but recent advances and discoveries in microRNAs (miRNAs) have opened the potential for new prognostication modalities to enhance therapeutic success. As new chemotherapies and immunotherapies are developed, there is an increasing need for precision and stratification of CRPC to allow for optimization and personalization of therapy.

METHODS

A systematic literature review was conducted via electronic database resulting in the selection of 42 articles based on title, abstract, study format, and content by a consensus of all participating authors. Most selected articles were published between 2002 and 2013. In this review, we discuss the robustness of miRNAs as a biomarker platform, miRNAs associated with prostate cancer, and recent discoveries of miRNA associations with CRPC.

RESULTS

The associations discovered have been of interest owing to the ability to differentiate between CRPC and localized prostate cancer. With the evaluation of multiple miRNAs, it is possible to provide a profile regarding tumor characteristics. Furthermore, actions of miRNAs on CRPC tumor cells have the ability to suppress metastatic phenotypes.

CONCLUSION

miRNAs may have a growing role in CRPC prognostication and may potentially transform into a therapeutic potential.

摘要

引言

去势抵抗性前列腺癌(CRPC)的历史中位生存率较低,但近年来微小RNA(miRNA)领域的进展和发现为新的预后评估方式带来了可能,有望提高治疗成功率。随着新的化疗和免疫疗法的不断研发,对CRPC进行精准分类和分层的需求日益增加,以便实现治疗的优化和个性化。

方法

通过电子数据库进行系统的文献综述,所有参与作者共同根据标题、摘要、研究形式和内容筛选出42篇文章。大多数入选文章发表于2002年至2013年之间。在本综述中,我们讨论了miRNA作为生物标志物平台的稳健性、与前列腺癌相关的miRNA以及最近发现的miRNA与CRPC的关联。

结果

所发现的关联因其能够区分CRPC和局限性前列腺癌而备受关注。通过评估多种miRNA,可以提供有关肿瘤特征的概况。此外,miRNA对CRPC肿瘤细胞的作用具有抑制转移表型的能力。

结论

miRNA在CRPC预后评估中可能发挥越来越重要的作用,并有可能转化为一种治疗潜力。

相似文献

1
The role of microRNA in castration-resistant prostate cancer.
Urol Oncol. 2014 Jul;32(5):517-523. doi: 10.1016/j.urolonc.2013.11.004.
2
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
5
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
7
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
8
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.

引用本文的文献

2
Bioinformatics-Assisted Extraction of All PCa miRNAs and their Target Genes.
Microrna. 2024;13(1):33-55. doi: 10.2174/0122115366253242231020053221.
3
Tumor suppressive miR-99b-5p as an epigenomic regulator mediating mTOR/AR/SMARCD1 signaling axis in aggressive prostate cancer.
Front Oncol. 2023 Nov 7;13:1184186. doi: 10.3389/fonc.2023.1184186. eCollection 2023.
4
miRNAs: Potential as Biomarkers and Therapeutic Targets for Cancer.
Genes (Basel). 2023 Jun 29;14(7):1375. doi: 10.3390/genes14071375.
6
The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer.
J Cancer Res Clin Oncol. 2022 Oct;148(10):2893-2910. doi: 10.1007/s00432-022-04213-9. Epub 2022 Aug 4.
7
Circulating microRNAs as Reliable Tumor Biomarkers: Opportunities and Challenges Facing Clinical Application.
J Pharmacol Exp Ther. 2023 Jan;384(1):35-51. doi: 10.1124/jpet.121.000896. Epub 2022 Jul 9.
8
MicroRNAs as Potential Liquid Biopsy Biomarker for Patients with Castration-Resistant Prostate Cancer.
Res Rep Urol. 2022 Mar 1;14:63-70. doi: 10.2147/RRU.S332578. eCollection 2022.

本文引用的文献

1
A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer.
Tumour Biol. 2013 Oct;34(5):3159-63. doi: 10.1007/s13277-013-0885-x. Epub 2013 Jun 2.
2
miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.
Oncogene. 2014 May 8;33(19):2495-503. doi: 10.1038/onc.2013.200. Epub 2013 Jun 3.
3
Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.
PLoS One. 2013 Apr 9;8(4):e61064. doi: 10.1371/journal.pone.0061064. Print 2013.
4
Cancer statistics, 2013.
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
5
The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells.
PLoS One. 2012;7(12):e52106. doi: 10.1371/journal.pone.0052106. Epub 2012 Dec 26.
6
Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells.
Oncogene. 2013 Aug 29;32(35):4130-8. doi: 10.1038/onc.2012.425. Epub 2012 Oct 15.
7
Functional p53 determines docetaxel sensitivity in prostate cancer cells.
Prostate. 2013 Mar;73(4):418-27. doi: 10.1002/pros.22583. Epub 2012 Sep 19.
9
MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth.
PLoS One. 2012;7(3):e32832. doi: 10.1371/journal.pone.0032832. Epub 2012 Mar 30.
10
MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells.
J Biol Chem. 2012 Jan 6;287(2):1527-37. doi: 10.1074/jbc.M111.278705. Epub 2011 Nov 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验